scholarly journals Effectiveness of glycosaminoglycan replacement treatment with intravesical instillation in patients with haemorrhagic radiation cystitis post-pelvic radiotherapy

2020 ◽  
Vol 19 ◽  
pp. e1409
Author(s):  
F. Sanguedolce ◽  
J. Meneghetti ◽  
B. Montaño ◽  
G. Bevilacqua ◽  
C. Martinez ◽  
...  
2007 ◽  
Vol 177 (4S) ◽  
pp. 22-22
Author(s):  
Yung C. Chow ◽  
Jong M. Hsu ◽  
Wen C. Lin ◽  
Huang K. Chang ◽  
Yuh C. Yang ◽  
...  

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Bernadette Zwaans ◽  
Sarah Bartolone ◽  
Michael Chancellor ◽  
Peter Levanovich ◽  
Sarah Krueger ◽  
...  

2020 ◽  
Vol 13 (11) ◽  
Author(s):  
Farzad Allameh ◽  
Abbas Basiri ◽  
Saleh Ghiasy ◽  
Atefeh Javadi ◽  
Seyyed Ali Hojjati ◽  
...  

Background: Radiotherapy (RT) is a choice to manage pelvic organ malignancies that can affect bladder; therefore, it causes radiation cystitis with some bothering urinary symptoms and decreasing the patient’s quality of life. Intravesical hyaluronic acid (HA) is an agent with promising results in some studies for cystitis, and Cystistat is a derivative of hyaluronic acid. Objectives: This clinical trial aimed at evaluating the effects of intravesical instillation of Cystistat on symptoms of radiation cystitis and quality of life (QOL). Methods: A total of 58 patients with radiation cystitis were randomized in 2 groups (case: 30, control: 28). One group received intravesical Cystistat, the other received normal saline weekly for up to 4 weeks and then monthly for up to 2 months. Hematuria, Visual Analog scale (VAS) and QOL based on King’s Health questionnaire were compared before and 3, 6 and 9 months after intravesical instillation. Results: The mean age of the patients was 63.93 ± 10.89 years old. The mean of each sub-category of QOL and total score of QOL, as well as, VAS score were significantly improved in comparison to the control group at each time of follow-ups (P < 0.05). Hematuria was significantly different in the 3rd, 6th and 9th month of follow-ups (P < 0.05). Conclusions: Findings showed that patients with radiation cystitis could significantly benefit from intravesical instillation of HA, their hematuria would be successfully resolved rather than control group in addition to lowering the VAS score, so their QOL would be improved.


2019 ◽  
Vol 27 (2) ◽  
pp. 98-107 ◽  
Author(s):  
Lauren Villeirs ◽  
Thomas Tailly ◽  
Piet Ost ◽  
Marjan Waterloos ◽  
Karel Decaestecker ◽  
...  

Author(s):  
Michele MARCHIONI ◽  
Piergustavo DE FRANCESCO ◽  
Riccardo CAMPI ◽  
Umberto CARBONARA ◽  
Matteo FERRO ◽  
...  

2020 ◽  
Vol 21 (3) ◽  
pp. 120-130
Author(s):  
E. I. Gutrova ◽  
◽  
D. I. Petrov ◽  
T. B. Grigorenko ◽  
A. A. Simonov ◽  
...  

The data presented in the review indicate that despite modern advances in chemotherapy, hormonal therapy, targeted therapy, and immunotherapy of neoplasms, radiation therapy is a common method of treating malignant tumors of various localization. The most compelling evidence of efficacy exists for systemic therapy with TCDO / WF10, cranberry capsules, hyperbaric oxygen therapy, and intravesical instillation of hyaluronic acid preparations. The presence of many methods of treatment of radiation-induced cystitis described in the literature: systemic, local with the use of physical methods, combinations of different methods – indicates the absence of a single concept for the prevention and treatment of this severe complication of radiation therapy justifies the relevance of further study of treatment protocols from the standpoint of evidence-based and personalized medicine.


Clinics ◽  
2019 ◽  
Vol 74 ◽  
Author(s):  
Vítor Fonseca Xavier ◽  
Flávia Carolina Grosso Gabrielli ◽  
Karim Yaqub Ibrahim ◽  
Mariana Vilela Soares Gomes ◽  
Roger Guilherme Rodrigues Guimarães ◽  
...  

Clinics ◽  
2019 ◽  
Vol 74 ◽  
Author(s):  
Vítor Fonseca Xavier ◽  
Flávia Carolina Grosso Gabrielli ◽  
Karim Yaqub Ibrahim ◽  
Mariana Vilela Soares Gomes ◽  
Roger Guilherme Rodrigues Guimarães ◽  
...  

1996 ◽  
Vol 28 (5) ◽  
pp. 643-647 ◽  
Author(s):  
M. Miura ◽  
I. Sasagawa ◽  
Y. Kubota ◽  
Y. Iijima ◽  
T. Sawamura ◽  
...  

Author(s):  
А.В. Бойко ◽  
Н.Д. Олтаржевская ◽  
В.И. Швец ◽  
Л.В. Демидова ◽  
Е.А. Дунаева ◽  
...  

Цель исследования. Разработка методов сопроводительной терапии для защиты нормальных органов и тканей, входящих в зону облучения. Методы. В исследование включено 112 больных раком шейки и тела матки после комбинированного или самостоятельного лучевого лечения с 2012 по 2016 гг. У 71 пациентки основной группы в качестве терапии сопровождения применяли гидрогель с деринатом и у 41 больной группы контроля - традиционные методы профилактики (масло оливковое, подсолнечное, метилурациловая мазь). Для профилактики эпителиита слизистой влагалища и шейки матки в основной группе использовали гидрогель в виде аппликаций с первого дня облучения. Для профилактики лучевого ректита гидрогель вводили в прямую кишку 1 раз в день с первого дня облучения. Инстилляции гидрогеля в мочевой пузырь начинали только при развитии первых признаков клинической картины цистита. Пациенткам контрольной группы для профилактики лучевых реакций проводились масляные, мазевые аппликации во влагалище, масляные микроклизмы в прямую кишку с первого дня облучения. Лечение лучевого цистита проводили с помощью растительных диуретиков, уросептиков. Результаты. Применение гидрогеля с деринатом позволило провести курс лучевой терапии без перерыва у 84,5% (60/71) больных, в контрольной группе - лишь у 48,8% (20/41). Лучевые циститы возникали в 2,5 раза реже (25,3% ± 3,3 против 63,4% ± 2,7, р<0,01). Анализ степени выраженности лучевого цистита по RTOG в двух группах показал, что у 75% больных основной группы наблюдалась I степень, у 25% - II степень, III и IV степени не отмечено, тогда как в контрольной группе лучевой цистит I степени развился у 44% пациенток, II - 40% и III - 16% больных. Применение гидрогеля снизило частоту лучевых ректитов в 2 раза (26,7% ± 3,3 против 53,7% ± 3,2 р<0,1).При использовании ежедневных аппликаций гидрогеля с деринатом со стороны слизистой оболочки влагалища и шейки матки преобладали эпителииты I степени (53,5%), II степень наблюдалась у 29,5% и III степень лучевой реакции - лишь в 16,9% случаев, IV степень реакции не отмечена. В контрольной группе эти показатели составили 26,8%, 24,3%, 31,7% и 17,2% соответственно. Разработаны цитологические критерии оценки течения лучевых реакций слизистой влагалища. Выделены три степени изменения цитограммы, которые коррелировали с клинической картиной. В основной группе лучевые изменения I степени зафиксированы в 4,5 раза чаще (52 ± 9,9% против 11,5 ± 6,3%, р<0,002), а III степень представлена в 3,8 раза реже, чем в контрольной группе (12 ± 6,5% против 46,1 ± 9,8%, р<0,003). Заключение. Применение гидрогелевого материала с деринатом в качестве препарата сопроводительной терапии во время курса облучения позволяет уменьшить частоту и степень выраженности лучевых повреждений со стороны слизистой влагалища, мочевого пузыря и прямой кишки, провести курс лучевой терапии без перерыва и улучшить качество жизни пациенток. Objective. Development of methods for accompanying therapy to protect normal organs and tissues in the irradiation zone. Method. The study included 112 patients with cervical and endometrial cancer after combined or independent radiotherapy from 2012 to 2016. In 71 female patients of the main group, Derinat with hydrogel was applied as a supportive therapy and in 41 patients of the control group, conventional prevention methods (olive oil, sunflower oil, methyluracyl ointment) were applied. For prevention of vaginal mucosal and cervical epitheliitis in the main group, hydrogel was used as applications from the first radiation day. For prevention of radiation proctitis, hydrogel was injected into the rectum once daily from the first radiation day. Hydrogel instillations into the bladder were started only with the first clinical signs of cystitis. For prevention of radiation reactions, vaginal oil and ointment and rectal oil micro-enema were administered to patients of the control group from the first day of irradiation. Radiation cystitis was treated with vegetable diuretics and uroseptic drugs. Results. Using the hydrogel with Derinat allowed to administer a course of radiotherapy without interruption in 84.5% (60/71) of patients and only in 48.8% (20/41) in the control group. Radiation cystitis occurred 60% less frequently (25.3% ± 3.3 versus 63.4% ± 2.7, p <0.01). Analysis of radiation cystitis severity in two groups (according to RTOG) showed that 75% of patients in the main group had grade I and 25% had grade II. Grade III and grade IV did not occur. At the same time, in the control group, grade I radiation cystitis developed in 44% of patients, grade II - in 40%, and grade III - in 16% of patients. The hydrogel treatment halved the frequency of radiation proctitis (26.7% ± 3.3 vs. 53.7% ± 3.2 p <0.1). With daily application of the hydrogel with Derinat, grade I epitheliitis (53.5%) predominated in vaginal and cervical mucosa, grade II was observed in 29.5%, and grade III radiation reaction - only in 16.9% of cases; grade IV reaction was not observed. In the control group, these proportions were 26.8%, 24.3%, 31.7%, and 17.2%, respectively. Cytological criteria were developed to evaluate the course of radiation reactions in the vaginal mucosa. Three degrees of change in the cytogram were identified, which correlated with clinical picture. In the main group, incidence of grade I radiation-induced changes was increased by more than 350% (52 ± 9.9% vs. 11.5 ± 6.3%, p <0.002), and incidence of grade III was decreased by more than 70% compared to the control group (12 ± 6.5% vs. 46.1 ± 9.8%, p <0.003). Conclusion. Using the hydrogel material with Derinat as an accompanying therapy during the course of irradiation allows to reduce frequency and severity of radiation injuries of the vaginal mucosa, bladder, and rectum, administer an uninterrupted course of radiotherapy, and improve the quality of life of patients.


Sign in / Sign up

Export Citation Format

Share Document